Rigel Announces U.S. FDA Approval Of REZLIDHIA (olutasidenib) For Treatment Of Adult Patients With Relapsed Or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that the U.S. Food and Drug Administration (FDA) has approved REZLIDHIA™ (olutasidenib) capsules for the treatment of adult patients with relapsed or